TCT 2019 | EXCEL: Left Main Coronary Artery Angioplasty with Favorable Results at 5 Years

Courtesy of Dr. Carlos Fava.

Unprotected left main coronary artery angioplasty with drug-eluting stents has emerged as an acceptable strategy for a select group of patients, with results comparable to those of myocardial revascularization surgery at 2 or 3 years. However, beyond such term, we had no valid information.

Highlights TCT 2019

Researchers analyzed the 5-year follow-up results for the EXCEL trial, which randomized 948 patients with an intermediate or low SYNTAX score to undergo angioplasty with an everolimus-eluting stent (XIENCE, Abbott Vascular) while others were randomized to coronary artery revascularization surgery.

The primary endpoint at 5 years consisted of death, stroke, or infarction, while the secondary endpoint at 5 years was a composite of death, stroke, infarction, and ischemia-driven revascularization.

Groups were similar: the mean age was 66 years old, most patients were male, and 30% of subjects had diabetes. The SYNTAX score was 20.6 ± 6.2 for local sites and 26.5 ± 6.3 for core lab with angiography. About 80.5% of patients had severe bifurcation lesion in the left main coronary artery.


Read also: TCT 2019 | AUGUSTUS ACS: Apixaban vs. Warfarin and Aspirin vs. Placebo in AF and ACS.


Over 90% of patients in both groups completed the 5-year follow-up. There were no differences in the primary endpoint (22% for angioplasty and 19.2% for myocardial revascularization surgery; p = 0.13). The secondary endpoint favored myocardial revascularization surgery (24.1% vs. 31.2%; p = 0.002), driven by a higher need for ischemia-driven revascularization (16.9% vs. 10%; p > 0.001). There were no differences as regards cardiac death, infarction, or stroke. Non-cardiac death rates were higher in the angioplasty group.

Conclusion

In patients with unprotected left main coronary artery disease who had intermediate or low anatomical complexity, there were no differences between angioplasty and myocardial revascularization surgery as regards death, stroke, or infarction after a 5-year follow-up.

Courtesy of Dr. Carlos Fava.

Link to the SBHCI Publication HERE

excel

excel-5yearpdf

Original Title: EXCEL: 5-Year Outcomes From a Randomized Trial of PCI vs. CABG in Patients With Left Main Coronary Artery Disease.

Author of the Original Title: Gregg W. Stone.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....